PROGRAM - Monday, May 17, 2010

PROGRAM - MONDAY, MAY 17, 2010
 
7:00AM - 8:00AM
EDUCATIONAL SYMPOSIUM (Sponsored by Medaxial)
THE 7 ESSENTIALS OF SUCCESSFUL HEALTH ECONOMIC COMMUNICATION Symposium Description »
8:00AM - 8:30AM
EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
8:30AM - 10:30AM
WELCOME & FIRST PLENARY SESSION

MEETING PROGRAM OVERVIEW
Daniel C. Malone RPh, PhDDaniel C. Malone RPh, PhD
Professor, College of Pharmacy, University of Arizona, Tucson, AZ, USA
 

PRESIDENTIAL ADDRESS
Michael Barry PhD Michael Barry PhD
2009-2010 ISPOR President & Clinical Director, National Centre for Pharmacoeconomics, St. James’s Hospital and Senior Lecturer in Clinical Pharmacology, Trinity College Dublin, Dublin, Ireland
  Personalized Medicine: The Value of Targeted Therapy
The mapping of the human genome has opened the gate for developing therapies that benefit select subsets of the population. This plenary session will provide an introduction to pharmacogenomics and pharmacogenetics, debate the role of genotyping, present case studies where therapies are being tailored to specific genetic disposition, and discuss the role of pharmacoeconomics and outcomes research in defining the value of personalized medicine.

9:00 – 9:20 AM   Moderator/Speaker: Scott D. Ramsey MD, PhD, Full Member and Professor, Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA, USA
     
9:20 – 9:40 AM   Speaker: Lawrence J. Lesko PhD, FCP, Director, Office of Clinical Pharmacology, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
     
9:40 – 10:00 AM   Speaker: Ralph J. Coates PhD, Associate Director for Science, Office of Public Health Genomics, Centers for Disease Control and Prevention, Atlanta, GA, USA
     
10:00 – 10:20 AM   Speaker: Robert S. Epstein MD, MS, Chief Medical Officer and President, Medco Research Institute, Medco Health Solutions Inc., Franklin Lakes, NJ, USA
     
10:20 – 10:30 AM   DISCUSSION
10:30AM-11:00AM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
11:00AM-12:00PM
ISSUE PANELS – SESSION I
 

Clinical Outcomes Research Issues
11:00AM-12:00PM
IP1: HETEROGENEITY OF TREATMENT EFFECTS: A REASSESSMENT IN THE ERA OF COMPARATIVE EFFECTIVENESS RESEARCH
Moderator: David Thompson PhD, Vice President, Global Health Economics, i3 Innovus, Medford, MA, USA
Panelists: John Cook PhD, Senior Director, Scientific Staff, Health Economics Statistics, Merck & Co., Inc., North Wales, PA, USA; Sheldon Greenfield MD, Professor of Medicine and Executive Director, Center for Health Policy Research, School of Medicine, University of California, Irvine, Irvine, CA, USA
  Health Policy Development Using Outcomes Research Issues
11:00AM-12:00PM
IP2: MEDICARE, HEALTH REFORM AND THE FUTURE OF EVIDENCE REQUIREMENTS
Moderator: Peter J. Neumann ScD, Professor, Tufts University School of Medicine and Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
Panelists: Steve E. Phurrough MD, MPA, (Formerly at CMS), Chief Operating Officer and Senior Clinical Director, Center for Medical Technology Policy, Baltimore, MD, USA; Penny Mohr MA, (Formerly at CMS), Vice President, Programs, Center for Medical Technology Policy, Baltimore, MD, USA; James Chambers MPharm, MSc, Project Director, The Center for the Evaluation of Value and Risk in Health, The Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, USA
11:00AM-12:00PM
IP3: PERSPECTIVES ON COMPARATIVE EFFECTIVENESS RESEARCH (CER): VIEWS FROM DIVERSE CONSTITUENCIES
Moderator: Howard Birnbaum PhD, Principal, Analysis Group, Inc., Boston, MA, USA
Panelists: Marc L. Berger MD, Vice President, Global Health Outcomes, Eli Lilly and Company, Indianapolis, IN, USA; Jean Slutsky PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Robert S. Epstein MD, MS, Chief Medical Officer and President, Medco Research Institute, Medco Health Solutions Inc., Franklin Lakes, NJ, USA
  Patient-Reported Outcomes Research Issues
11:00AM-12:00PM
IP4: PATIENT-REPORTED OUTCOMES FOR ADVERSE EVENT MONITORING
Moderator: Ethan Basch MD, MSc, Principal Investigator, Health Outcomes Group, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Panelists: Laurie B. Burke RPh, MPH, Director, Study Endpoint and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; Bryce Reeve PhD, Program Director, National Cancer Institute, Bethesda, MD, USA; Stephen Joel Coons PhD, Director, Patient-Reported Outcomes (PRO) Consortium, Critical Path Institute, Tucson, AZ, USA
12:00PM-1:45PM
LUNCH, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
12:30PM-1:30PM
EDUCATIONAL SYMPOSIUM (Sponsored by IMS)
WILL COMPARATIVE EFFECTIVENESS RESEARCH SURVIVE HEALTH REFORM? Symposium Description »
1:45PM-2:45PM
RESEARCH PODIUM PRESENTATIONS – SESSION I
1:45PM-2:45PM

RESEARCH ON DATABASE METHODS

DB1: DEVELOPMENT AND VALIDATION OF A MODEL TO PREDICT VIROLOGIC FAILURE USING ADMINISTRATIVE CLAIMS

Juday T1, Jing Y1, Chang E2, Broder M2
1Bristol-Myers Squibb, Plainsboro, NJ, USA, 2Partnership for Health Analytic Research, LLC, Beverly Hills, CA, USA

DB2: EVALUATION OF AGREEMENT BETWEEN INTERNET-BASED SELF- AND PROXY-REPORTED HEALTH CARE UTILIZATION AND ADMINISTRATIVE HEALTH CARE CLAIMS

Palmer L1, Johnston SS1, Rousculp M2, Nichol KL3, Mahadevia PJ2
1Thomson Reuters, Washington, DC, USA, 2MedImmune, Gaithersburg, MD, USA, 3University of Minnesota, Minneapolis, MN, USA

DB3: MUCH ADO ABOUT THE LACK OF SOCIO-ECONOMIC COVARIATES IN ADMINISTRATIVE CLAIMS DATA

Borah B
i3 Innovus, Eden Prairie, MN, USA

DB4: ACCOUNTING FOR THE RELATIONSHIP BETWEEN PER DIEM COST AND LOS WHEN ESTIMATING HOSPITALIZATION COSTS

Stolar M1, Hu MY2, Ishak K3, Wang Y2, Williams GC2, Ferguson J2, Getsios D4, Alvarez P1
1United BioSource Corporation, Lexington, MA, USA, 2The Medicines Company, Parsippany, NJ, USA, 3United BioSource Corporation, Dorval, QC, Canada, 4United BioSource Corporation, Halifax, NS, Canada
1:45PM-2:45PM

HEALTH CARE EXPENDITURES STUDIES

HE1: COST-EFFECTIVENESS OF 1ST LINE CHEMOTHERAPY REGIMENS IN THE TREATMENT OF NON-SMALL CELL LUNG CANCER AMONG PATIENTS RECEIVING CARE IN THE OUTPATIENT COMMUNITY SETTING

Hoverman JR1, Pohl G2, Gruschkus SK3, Marciniak M2, Forsyth M3, Peltz G2
1Texas Oncology, Dallas, TX, USA, 2Eli Lilly and Company, Indianapolis, IN, USA, 3Healthcare Informatics, The Woodlands, TX, USA

HE2: HEALTH CARE COSTS OF METASTATIC SQUAMOUS CELL CARCINOMA OF HEAD AND NECK - FINDINGS FROM LINKED SEER-MEDICARE DATA

Parthan A1, Kulakodlu M2, Deflin M1, Taylor D3, Barber B4, Zhao Z4
1i3 Innovus, San Francisco, CA, USA, 2i3 Innovus, Eden Prairie, MN, USA, 3i3 Innovus, Medford, MA, USA, 4Amgen Inc., Thousand Oaks, CA, USA

HE3: CAN INNOVATION BE REWARDED WITH THE APPLICATION OF RIGID COST-EFFECTIVENESS THRESHOLDS? THE HER2+VE BREAST CANCER CASE STUDY

Ray J, Cirrincione A
F. Hoffmann-La Roche Ltd., Basel, Switzerland

HE4: CHARACTERIZATION OF FREQUENT HOSPITAL EMERGENCY DEPARTMENT (ED) USE BY UN- OR UNDERINSURED PERSONS

Khurshid A1, Strassels S2
1Integrated Care Collaboration, Austin, TX, USA, 2University of Texas at Austin, Austin, TX, USA
1:45PM-2:45PM

HEALTH TECHNOLOGY ASSESSMENT STUDIES

HT1: COMPARATIVE-EFFECTIVENESS VERSUS COST-EFFECTIVENESS: A COMPARISON OF THE FRENCH AND SCOTTISH APPROACHES TO SINGLE TECHNOLOGY ASSESSMENT (STA)

Bending MW1, Hutton J1, McGrath C2
1University of York, York, UK, 2Pfizer, Walton on the Hill, Surrey, UK

HT2: VARIABILITY IN UTILIZATION OF INNOVATIVE DRUGS IN EUROPE AS A RESULT OF HEALTH TECHNOLOGY ASSESSMENT AND FUNDING PROCEDURES: EXAMPLES OF TRASTUZUMAB AND CETUXIMAB

Toumi M1, Misset JL2, Cristeau O1, Krukowski L3, Aballea S4, Lamure M5
1University Claude Bernard Lyon 1, Lyon, France, 2Hopital Saint Louis, Paris, France, 3Synovate, London, UK, 4CREATIV-CEUTICAL, Paris, France, 5University Claude Bernard Lyon 1, Paris, France

HT3: MULTICRITERIA DECISION ANALYSIS (MCDA) FOR DRUG COVERAGE DECISION BY A PUBLIC HEALTH PLAN: CASE STUDY OF TRAMADOL FOR CHRONIC NON-CANCER PAIN (CNCP) IN CANADA

Tony M1, Goetghebeur M1, Wagner M1, Khoury H1, Rindress D1, Oh P2
1BioMedCom Consultants Inc., Dorval, QC, Canada, 2University of Toronto, Toronto, ON, Canada

HT4: PRAGMATIC CLINICAL TRIALS FOR DRUG APPROVAL: IS IT REALISTIC?

Mohr P1, Sonnad S2, Mullins CD3, Whicher D1, Goldsack J2, Tunis SR1
1Center for Medical Technology Policy, Baltimore, MD, USA, 2University of Pennsylvania, Philadelphia, PA, USA, 3University of Maryland School of Pharmacy, Baltimore, MD, USA
1:45PM-2:45PM

RESEARCH ON PRO METHODS (INCLUDING UTILITIES)

PR1: INCORPORATING TARIFF-LEVEL UNCERTAINTY AROUND ESTIMATES FROM THE CATALOGUE OF EQ-5D SCORES

Sullivan P1, Ghushchyan VH2, Slejko JF2
1Regis University School of Pharmacy, Denver, CO, USA, 2University of Colorado Denver, Aurora, CO, USA

PR2: EVALUATING THE MEASUREMENT PROPERTIES OF AN AUGMENTED EQ-5D WITH THE INCLUSION OF TWO SINGLE QUALITY-OF-LIFE (QOL) INDICATORS USING THE MEDICAL EXPENDITURE PANEL SURVEY (MEPS)

Gu NY1, Bond TG2, Craig BM3
1Pharmerit North America, LLC, Bethesda, MD, USA, 2James Cook University, Townsville, QLD, Australia, 3Moffitt Cancer Center, Tampa, FL, USA

PR3: NATIONAL CULTURE AND EQ-5D VALUE SETS

Bailey H1, Kind P2
1The University of the West Indies, Maracas Valley, Trinidad and Tobago, 2University of York, York, UK

PR4: ARE HEALTH STATES "TIMELESS"? A TEST OF THE UTILITY INDEPENDENCE ASSUMPTION: COMPARING A REPEATED MEASURES DESIGN AND LATENT GROWTH MODELING

Franic D1, Gafni A2, Vandenberg R1
1University of Georgia, Athens, GA, USA, 2McMaster University, Hamilton, ON, Canada
1:45PM-2:45PM

RISK MANAGEMENT STUDIES

RM1: COMPARATIVE PERFORMANCE OF RISK ADJUSTMENT MEASURES IN A SAMPLE OF COMMERCIALLY-INSURED PATIENTS UNDER AGE 65 - TWO SIMPLE MEASURES OUTPERFORM CURRENT STANDARDS

 Fowler R, Johnston SS
Thomson Reuters, Washington, DC, USA

RM2: IMPACT OF ADHERENCE WITH STATIN THERAPY ON HOSPITALIZATION RISK AND MORTALITY AMONG PATIENTS WITH DIABETES

 Yang Y, Banahan BF, P
ace PF University of Mississippi, University, MS, USA

RM3: RISK OF FALLS AND FRACTURES IN OLDER ADULTS USING ATIPSYCHOTIC AGENTS- A PROPENSITY-MATCHED RETROSPECTIVE COHORT STUDY

 Mehta S, Aparasu RR, Chen H, Johnson M
University of Houston, Houston, TX, USA

RM4: CONFOUNDING EFFECT OF AGE IN THE ASSOCIATION OF CARDIOVASCULAR RISK AND DIETARY SUPPLEMENT USE AMONG US ADULTS

 Yu S1, Shaw JW1, Crawford SY1, Groo V2
1University of Illinois at Chicago, Chicago, IL, USA, 2University of Illinois at Chicago, Chicago , IL, USA
3:00PM-4:00PM
WORKSHOPS – SESSION I
 

Clinical Outcomes Research Issues
3:00PM-4:00PM
W1: COMPARATIVE EFFECTIVENESS RESEARCH FOR PERSONALIZED MEDICINE
Discussion Leaders: James Signorovitch PhD, Manager, Analysis Group, Inc., Boston, MA, USA; Eric Q. Wu PhD, Vice President, Analysis Group, Inc., Boston, MA, USA; Lee-Jen Wei PhD, Professor, Biostatistics, Harvard University, Boston, MA, USA
  Economic Outcomes Research
3:00PM-4:00PM
W2: CHALLENGES IN DESIGNING, CONDUCTING AND ANALYSING MULTINATIONAL ECONOMIC CLINICAL TRIALS
Discussion Leaders: Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Andrea Manca PhD, MSc, Senior Research Fellow, Centre for Health Economics, University of York, York, UK; Arie Barlev PhD, Senior Manager, Global Health Economics, Amgen, Thousand Oaks, CA, USA
3:00PM-4:00PM
W3: COST OF ILLNESS STUDIES: A FRESH LOOK AT ONE OF THE FOUNDATIONS OF HEALTH POLICY AND OUTCOMES RESEARCH
Discussion Leaders: Tami Mark PhD, MBA, Director, Thomson Reuters, Washington, DC, USA; Dan Huse MA, VP, Outcomes Research, Thomson Reuters, Cambridge, MA, USA; Joel W. Hay PhD, Associate Professor, Pharmaceutical Economics & Policy, University of Southern California, Los Angeles, CA, USA
  Health Care Policy Development Using Outcomes Research
3:00PM-4:00PM
W4: THE 2009 UPDATE OF THE AMCP FORMAT FOR FORMULARY COVERAGE AND REIMBURSEMENT DECISIONS IN THE US
Discussion Leaders: Richard Fry RPh, Director of Programs, Foundation for Managed Care Pharmacy, Alexandria, VA, USA; Sean Sullivan PhD, RPh, MS, Professor and Director, Pharmaceutical Outcomes Research & Policy Program, Department of Pharmacy, University of Washington, Seattle, WA, USA; Pete Penna PharmD, President, Formulary Resources, LLC, Mercer Island, WA, USA; Iris Tam PharmD, Director, Institutional Medical Communications, Genentech, South San Francisco, CA, USA
  Patient-Reported Outcomes/PREFERENCE-BASED Research
3:00PM-4:00PM
W5: REGULATORY EVALUATION OF PATIENT-REPORTED OUTCOME MEASURES (PROS) USED IN CLINICAL TRIALS
Discussion Leaders: Laurie B. Burke RPh, MPH, Director, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; June Cai MD, Endpoints Reviewer, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; Ann Marie Trentacosti MD, Endpoints Reviewer, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; Donald Patrick PhD, Professor, Seattle Quality of Life Group, University of Washington, Seattle, WA, USA
3:00PM-4:00PM
W6: DEFINING A RESPONDER: IMPLEMENTING THE PATIENT-REPORTED OUTCOME (PRO) GUIDANCE RECOMMENDATIONS
Discussion Leaders: Lori McLeod PhD, Head, Psychometrics, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA; Ron D. Hays PhD, Professor of Medicine, Division of General Internal Medicine and Health Services Research, University of California at Los Angeles, Los Angeles, CA, USA; Susan Martin MSPH, Senior Director, Patient-Reported Outcomes, RTI Health Solutions, Ann Arbor, MI, USA; Sheri Fehnel PhD, Vice President, Patient-Reported Outcomes, RTI Health Solutions, Research Triangle Park, NC, USA
  USE OF REAL WORLD DATA
3:00PM-4:00PM
W7: HOW TO USE ADMINISTRATIVE CLAIMS DATABASES TO ASSESS LONG TERM CLINICAL BENEFIT OF MEDICATION INITIATION FROM AN EVOLUTIONARY PERSPECTIVE: TRADITIONAL ANALYTICAL APPROACHES VS. NOVEL USE OF TIME SERIES ANALYSIS
Discussion Leaders: Peter Sun MD, PhD, Vice President, Kailo Research Group, Indianapolis, IN, USA; Joanne R. Chang PhD, MD, Vice President, Evidence Based Medicine, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA; Jie Zhang PhD, Associate Director, Novartis Pharmaceuticals Corporation, East Hanover, NJ, USA
4:00PM-4:15PM
BREAK, EXHIBITS & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
4:15PM-5:15PM
WORKSHOPS – SESSION II
 

Clinical Outcomes Research Issues
4:15PM-5:15PM
W8: MODEL ASSUMPTIONS IN MIXED TREATMENT COMPARISONS (MTCS): WHY THEY MATTER AND WHY YOU SHOULD CARE
Discussion Leaders: Rachael Fleurence PhD, Senior Research Scientist, Center for Health Economics and Science Policy, United BioSource Corporation, Bethesda, MD, USA; Kyle Fahrbach PhD, Senior Biostatistician, United BioSource Corporation, Lexington, MA, USA; David Vanness PhD, Assistant Professor, Population Health Sciences, University of Wisconsin School of Medicine and Public Health, Madison, WI, USA
  Economic Outcomes Research
4:15PM-5:15PM
W9: THRESHOLD ANALYSIS TO CHARACTERIZE PARAMETER UNCERTAINTY IN COST-EFFECTIVENESS ANALYSES WITH AMBIGUOUS RESULTS
Discussion Leaders: Amy O'Sullivan PhD, Director, Health Economics & Outcomes Research, i3 Innovus, Medford, MA, USA; Milton C. Weinstein PhD, Henry J Kaiser Professor of Health Policy & Management, Harvard School of Public Health, Boston, MA, USA
4:15PM-5:15PM
W10: WHAT CAN RESOURCE ALLOCATION IN SITUATIONS OF EXTREME SCARCITY TELL US ABOUT THE ROLE OF THE QALY IN PRIORITY SETTING?
Discussion Leaders: Peter Kolominsky-Rabas PhD, MBA, Scientific Director, Interdisziplinäres Zentrum für Public Health (IZPH) der Universität Erlangen-Nürnberg, Erlangen, Germany; Georgia Mitsi PhD, MBA, MSc, Manager, United BioSource Corporation, Lexington, MA, USA; J. Jaime Caro MD, Senior Vice President of Health Economics, United BioSource Corporation, Lexington, MA, USA
  Health Care Policy Development Using Outcomes Research
4:15PM-5:15PM
W11: YOUR ROLE IN INTERPRETING AND APPROPRIATELY COMMUNICATING CER RESULTS IN A HIGHLY CHARGED ENVIRONMENT
Discussion Leaders: Robert Dubois PhD, MD, Chief Medical Officer, Cerner LifeSciences, Beverly Hills, CA, USA; Jean Slutsky PA, MSPH, Director, Center for Outcomes and Evidence, Agency for Healthcare Research and Quality, Rockville, MD, USA; Lester Paul MD, MS, Vice President, Clinical & Scientific Affairs, National Pharmaceutical Council, Reston, VA, USA; Brian Sweet RPh, MBA, Chief Pharmacy Officer, WellPoint, Grand Island, NY, USA
  Patient-Reported Outcomes/PREFERENCE-BASED Research
4:15PM-5:15PM
W12: INTERPRETATION OF PRO TRIAL RESULTS TO SUPPORT FDA LABELING CLAIMS
Discussion Leaders: Kathleen W. Wyrwich PhD, Senior Research Leader, Center for Health Outcomes Research, United BioSource Corporation, Bethesda, MD, USA; Laurie B. Burke RPh, MPH, Director, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA; Ann Marie Trentacosti MD, Endpoints Reviewer, Study Endpoints and Label Development, Center for Drug Evaluation and Research, Food and Drug Administration, Silver Spring, MD, USA
  USE OF REAL WORLD DATA
4:15PM-5:15PM
W13: PROJECTING DISEASE PREVALENCE: THE IMPACT OF METHODOLOGY– EXAMPLES IN ATRIAL FIBRILLATION
Discussion Leaders: Kathy L. Schulman MA, Principal, Outcomes Research Solutions, Inc., Bolton, MA, USA; Stephen S. Johnston MA, Research Leader, Outcomes Research, Thomson Reuters, Washington, DC, USA; Jay Lin PhD, MBA, Director, Evidence Based Medicine, sanofi-aventis U.S., Bridgewater, NJ, USA; Dan Huse MA, Vice President, Outcomes Research, Thomson Reuters, Cambridge, MA, USA
4:15PM-5:15PM
W14: POST-APPROVAL RESEARCH: ALTERNATIVE STUDY DESIGNS AND OPERATIONAL CONSIDERATIONS
Discussion Leaders: Cynthia Verst PharmD, MS, Senior Vice President, Late Phase Research, i3 Innovus, Cold Spring, KY, USA; Michael Drummond PhD, Professor of Health Economics, Centre for Health Economics, University of York, York, UK; Myoung Kim PhD, MA, MBA, Director, Health Economics & Outcomes Research, Ortho-McNeil Janssen Scientific Affairs, Raritan, NJ, USA; Frank Lobeck PharmD, Vice President, Americas, Late Phase Research, i3 Innovus, Dexter, MI, USA
5:30PM-6:30PM
ISPOR FORUMS
5:30PM-6:30PM ISPOR RECOMMENDATIONS ON THE FDA’S GUIDANCE FOR INDUSTRY PATIENT REPORTED OUTCOME MEASURES: USE IN MEDICAL PRODUCT DEVELOPMENT TO SUPPORT LABELING CLAIMS
The ISPOR Good Research Practices for the Assessment of Patient-Reported Outcomes in Children and Adolescents Task Force will present their findings.   The Good Research Practices for Establishing and Reporting Evidence of the Content Validity is presenting their manuscript on addressing content validity for newly developed PROs.  Presented by the ISPOR Patient Reported Outcomes Good Research Practices Task Forces.
5:30PM-6:30PM ISSUES AND CHALLENGES IN THE DEVELOPMENT AND REIMBURSEMENT OF PERSONALIZED MEDICINE
The applications of health outcomes and economic research for addressing issues and challenges in the development and reimbursement of Personalized Medicine will be discussed. Presented by the ISPOR Personalized Medicine Special Interest Group
5:30PM-6:30PM THE ISPOR GLOBAL HEALTH CARE SYSTEMS ROAD MAP – MOVING FORWARD WITH HTA FOR MEDICAL DEVICES & DIAGNOSTIC PRODUCTS!
ISPOR Global Health Care Systems Road Map will be used as a tool to discuss and compare the similarities and differences between the decision-making bodies and reimbursement and pricing approval process for products being assessed – pharmaceuticals, medical devices or diagnostics. Road maps for medical devices & diagnostics will be discussed together with some pragmatic solutions to the current issues associated with assessing their value. Presented by the ISPOR HTA Special Interest Group
5:30PM-6:30PM INDIRECT TREATMENT COMPARISONS GOOD RESEARCH PRACTICES
The mission of this ISPOR Task Force is to develop and present a good research practice on indirect treatment comparisons that addresses key issues from the outcomes researcher’s perspective as well as key issues from the health care decision-maker’s perspective, the Task Force draft report will be discussed.  Presented by the ISPOR Indirect Treatment Comparison Task Force
5:30PM-6:30PM COMPLIANCE ISSUES AND WHY MEASUREMENT AND ANALYSIS ARE IMPORTANT
Compliance research requires an understanding about the best methodology to conduct studies including: randomized controlled clinical trials, observational, and quasi- experimental studies. Key considerations for researchers regarding the design, analysis and reporting of results of such studies will be reviewed. Presented by the ISPOR Medication Compliance & Persistence Special Interest Group
5:30PM-6:30PM ISPOR STUDENT FORUM: DEFINING YOUR CAREER PATH - FROM STRATEGIC JOB SEARCH SKILLS TO DECISION MAKING
A panel of experts will address how students should strategize a job search.  What are the important points a student should consider during a job search?  How should a CurriculumVitae be modified to appeal to employers in various sectors?  What are the pros and cons of jobs in industry versus academia and what might help a graduate decide to take one position over another? Organized by the ISPOR Student Council
6:30PM-7:30PM
ISPOR FORUMS
6:30PM-7:30PM HEALTH CARE IN RUSSIA: ISSUES, CHALLENGES, SOLUTIONS
The forum will focus on a discussion of the most current health care issues in Russia. Presented by the ISPOR Russia Chapter
6:30PM-7:00PM
ISPOR ANNUAL BUSINESS MEETING
6:30PM-7:30PM
POSTER AUTHOR DISCUSSION HOUR – SESSION I
6:30PM-8:30PM
EXHIBITORS’ OPEN HOUSE RECEPTION & RESEARCH POSTER PRESENTATIONS VIEWING – SESSION I
 


Contact ISPOR @ info@ispor.org  |  View Legal Disclaimer
©2010 International Society for Pharmacoeconomics and Outcomes Research. All rights reserved under International and Pan-American Copyright Conventions. 
Website design by Eagle Systems USA, Inc.